Curative Biotechnology Stock Performance
| CUBT Stock | USD 0.01 0.0001 1.43% |
On a scale of 0 to 100, Curative Biotechnology holds a performance score of 5. The firm shows a Beta (market volatility) of -0.25, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Curative Biotechnology are expected to decrease at a much lower rate. During the bear market, Curative Biotechnology is likely to outperform the market. Please check Curative Biotechnology's maximum drawdown and the relationship between the expected short fall and period momentum indicator , to make a quick decision on whether Curative Biotechnology's price patterns will revert.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Curative Biotechnology are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak fundamental drivers, Curative Biotechnology unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:400 | Last Split Date 2022-12-02 |
1 | Curative Biotechnology, Inc. Announces Letter to Shareholders | 11/18/2025 |
2 | United States Curative Therapeutics Market 2033 Growth Drivers, Key Players Investment Opportunities - openPR.com | 01/05/2026 |
3 | Curative Biotechnology Announces Canadian Patent Allowance | 01/23/2026 |
Curative Biotechnology Relative Risk vs. Return Landscape
If you would invest 0.65 in Curative Biotechnology on October 30, 2025 and sell it today you would earn a total of 0.04 from holding Curative Biotechnology or generate 6.15% return on investment over 90 days. Curative Biotechnology is currently generating 0.8279% in daily expected returns and assumes 12.2713% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Curative, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Curative Biotechnology Target Price Odds to finish over Current Price
The tendency of Curative Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.01 | 90 days | 0.01 | about 46.8 |
Based on a normal probability distribution, the odds of Curative Biotechnology to move above the current price in 90 days from now is about 46.8 (This Curative Biotechnology probability density function shows the probability of Curative Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Curative Biotechnology has a beta of -0.25 suggesting as returns on the benchmark increase, returns on holding Curative Biotechnology are expected to decrease at a much lower rate. During a bear market, however, Curative Biotechnology is likely to outperform the market. Additionally Curative Biotechnology has an alpha of 0.8574, implying that it can generate a 0.86 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Curative Biotechnology Price Density |
| Price |
Predictive Modules for Curative Biotechnology
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Curative Biotechnology. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Curative Biotechnology Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Curative Biotechnology is not an exception. The market had few large corrections towards the Curative Biotechnology's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Curative Biotechnology, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Curative Biotechnology within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.86 | |
β | Beta against Dow Jones | -0.25 | |
σ | Overall volatility | 0 | |
Ir | Information ratio | 0.06 |
Curative Biotechnology Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Curative Biotechnology for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Curative Biotechnology can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Curative Biotechnology is way too risky over 90 days horizon | |
| Curative Biotechnology has some characteristics of a very speculative penny stock | |
| Curative Biotechnology appears to be risky and price may revert if volatility continues | |
| Curative Biotechnology has a very high chance of going through financial distress in the upcoming years | |
| Curative Biotechnology currently holds 1.37 M in liabilities with Debt to Equity (D/E) ratio of 6.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Curative Biotechnology has a current ratio of 0.1, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Curative Biotechnology's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 132.32 K. Net Loss for the year was (3.56 M) with profit before overhead, payroll, taxes, and interest of 100.21 K. | |
| Curative Biotechnology currently holds about 126.85 K in cash with (1.02 M) of positive cash flow from operations. | |
| Curative Biotechnology has a poor financial position based on the latest SEC disclosures | |
| Latest headline from globenewswire.com: Curative Biotechnology Announces Canadian Patent Allowance |
Curative Biotechnology Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Curative Stock often depends not only on the future outlook of the current and potential Curative Biotechnology's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Curative Biotechnology's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 907.9 M | |
| Cash And Short Term Investments | 19.5 K |
Curative Biotechnology Fundamentals Growth
Curative Stock prices reflect investors' perceptions of the future prospects and financial health of Curative Biotechnology, and Curative Biotechnology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Curative Stock performance.
| Return On Equity | -3.98 | ||||
| Return On Asset | -0.64 | ||||
| Current Valuation | 7.4 M | ||||
| Shares Outstanding | 1.05 B | ||||
| Price To Sales | 158.53 X | ||||
| Revenue | 132.32 K | ||||
| Gross Profit | 100.21 K | ||||
| EBITDA | (2.35 M) | ||||
| Net Income | (3.56 M) | ||||
| Cash And Equivalents | 126.85 K | ||||
| Total Debt | 1.37 M | ||||
| Debt To Equity | 6.60 % | ||||
| Current Ratio | 0.10 X | ||||
| Book Value Per Share | (0.01) X | ||||
| Cash Flow From Operations | (1.02 M) | ||||
| Market Capitalization | 7.22 M | ||||
| Total Asset | 2.16 M | ||||
| Retained Earnings | (41.89 M) | ||||
| Working Capital | (4.42 M) | ||||
About Curative Biotechnology Performance
Assessing Curative Biotechnology's fundamental ratios provides investors with valuable insights into Curative Biotechnology's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Curative Biotechnology is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.3 K | 1.4 K | |
| Return On Tangible Assets | (5.03) | (4.78) | |
| Return On Capital Employed | 0.45 | 0.47 | |
| Return On Assets | (1.90) | (1.80) | |
| Return On Equity | 0.65 | 0.69 |
Things to note about Curative Biotechnology performance evaluation
Checking the ongoing alerts about Curative Biotechnology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Curative Biotechnology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Curative Biotechnology is way too risky over 90 days horizon | |
| Curative Biotechnology has some characteristics of a very speculative penny stock | |
| Curative Biotechnology appears to be risky and price may revert if volatility continues | |
| Curative Biotechnology has a very high chance of going through financial distress in the upcoming years | |
| Curative Biotechnology currently holds 1.37 M in liabilities with Debt to Equity (D/E) ratio of 6.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Curative Biotechnology has a current ratio of 0.1, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Curative Biotechnology's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 132.32 K. Net Loss for the year was (3.56 M) with profit before overhead, payroll, taxes, and interest of 100.21 K. | |
| Curative Biotechnology currently holds about 126.85 K in cash with (1.02 M) of positive cash flow from operations. | |
| Curative Biotechnology has a poor financial position based on the latest SEC disclosures | |
| Latest headline from globenewswire.com: Curative Biotechnology Announces Canadian Patent Allowance |
- Analyzing Curative Biotechnology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Curative Biotechnology's stock is overvalued or undervalued compared to its peers.
- Examining Curative Biotechnology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Curative Biotechnology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Curative Biotechnology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Curative Biotechnology's stock. These opinions can provide insight into Curative Biotechnology's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Curative Stock Analysis
When running Curative Biotechnology's price analysis, check to measure Curative Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Curative Biotechnology is operating at the current time. Most of Curative Biotechnology's value examination focuses on studying past and present price action to predict the probability of Curative Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Curative Biotechnology's price. Additionally, you may evaluate how the addition of Curative Biotechnology to your portfolios can decrease your overall portfolio volatility.